SAN JOSE, Calif., Feb. 25, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it has entered into a strategic alliance with ResearchDx to launch its Cchek™ Prostate Cancer Confirmation (Cchek™ PCC) test as a Laboratory Developed Test. ResearchDx is a CLIA certified, CAP Accredited laboratory located in Southern California. Once launched, Cchek™ PCC will be available to patients throughout the United States, with the exception of New York state, which requires additional regulatory certification.
ResearchDx will begin clinical validation of Cchek™ PCC with the goal of launching the test in the third quarter of 2019. The steps necessary to launch the test include running samples to train the neural network (Anixa's artificial intelligence application for analysis), followed by analytical and clinical validation. Cchek™ PCC is designed to confirm the presence of cancer in a preliminarily diagnosed patient prior to biopsy. ResearchDx will perform the test in its CLIA laboratory according to the Anixa developed protocols and Artificial Intelligence (AI) analysis.
Dr. Amit Kumar, CEO of Anixa Biosciences stated, "We are pleased to commence this non-exclusive partnership with ResearchDx to launch our test as a laboratory developed test. We are looking forward to enabling patients and physicians to utilize this test as a tool to help manage their prostate health."
"We have evaluated the market opportunity for Anixa's Cchek™ PCC, and we are excited about launching the test. After reviewing the performance of the test, which combines flow cytometry and artificial intelligence, we feel confident that we can reproduce the results and complete the requisite validations in our hands in our CLIA laboratory," stated Dr. Mathew Moore, Co-founder and Principal of ResearchDx.
About Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
ResearchDx operates a fully accredited and licensed CLIA (Clinical Laboratory Improvement Act), CAP (College of American Pathologists) and ISO (International Organization for Standardization) laboratory in Irvine, CA. Supported by experienced scientists and project managers, ResearchDx has extensive experience in various technologies, platforms and an in-depth understanding of the entire diagnostics pathway from discovery through final commercial product. Additional information is available at https://researchdx.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
SOURCE Anixa Biosciences, Inc.